{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:31:39Z","timestamp":1793377899425,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejso.2026.111947","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:40:02Z","timestamp":1781278802000},"page":"111947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nodal localisation with magnetic seed in patients with stage III melanoma receiving neoadjuvant immune checkpoint inhibitors, a feasibility study"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0017-7377","authenticated-orcid":false,"given":"Ellen","family":"Krabbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2689-4432","authenticated-orcid":false,"given":"Anne","family":"Huibers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0130-7296","authenticated-orcid":false,"given":"Fredrik","family":"W\u00e4rnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8898-8301","authenticated-orcid":false,"given":"Axel","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-0355","authenticated-orcid":false,"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.ejso.2026.111947_bib1","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejso.2026.111947_bib2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejso.2026.111947_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFNalpha2b or ipilimumab in resected high-risk melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.ejso.2026.111947_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMc1807505","article-title":"Adjuvant pembrolizumab in resected stage III melanoma","volume":"379","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejso.2026.111947_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.111947_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejso.2026.111947_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111947_bib8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN Guidelines(R) insights: melanoma: cutaneous, version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.ejso.2026.111947_bib9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41591-025-04158-9","article-title":"Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial","volume":"32","author":"Hoeijmakers","year":"2026","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejso.2026.111947_bib10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/bjs.9068","article-title":"Radioactive seed localization for non-palpable breast cancer","volume":"100","author":"Barentsz","year":"2013","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2026.111947_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241237907","article-title":"Radar-guided localization and resection for metastatic nodal and soft tissue melanoma: a single-institution retrospective study","volume":"31","author":"Beekman","year":"2024","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.ejso.2026.111947_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/bjs\/znaa083","article-title":"Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial","volume":"108","author":"Hartmann","year":"2021","journal-title":"Br J Surg"},{"issue":"3","key":"10.1016\/j.ejso.2026.111947_bib13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1245\/s10434-017-6270-z","article-title":"Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA trial) : a new tool to guide the excision of the clipped node after neoadjuvant treatment","volume":"25","author":"Siso","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111947_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/RLU.0000000000004934","article-title":"Radio-guided occult lesion localization with 99m Tc for the localization of nonpalpable melanoma and soft tissue sarcoma lesions: a feasibility study","volume":"49","author":"Reijers","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1016\/j.ejso.2026.111947_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ejso.2018.02.211","article-title":"Radioactive seed localisation of non-palpable lymph nodes - a feasibility study","volume":"44","author":"Hassing","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111947_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CMR.0b013e3283350527","article-title":"Radio-guided ultrasound lymph node localization: feasibility of a new technique for localizing and excising nonpalpable lymph nodes ultrasound suspicious for melanoma metastases","volume":"20","author":"Testori","year":"2010","journal-title":"Melanoma Res"},{"issue":"10","key":"10.1016\/j.ejso.2026.111947_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108485","article-title":"Magnetic seed localization is feasible for non-palpable melanoma, Merkel cell carcinoma, and soft tissue sarcoma lesions","volume":"50","author":"van der Burg","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111947_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/bjs.11168","article-title":"Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma","volume":"106","author":"Schermers","year":"2019","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.ejso.2026.111947_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","article-title":"Representativeness of the index lymph node for total nodal Basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma","volume":"157","author":"Reijers","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejso.2026.111947_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2313","article-title":"1685TiP SWE-NEO: swedish neoadjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4\/anti-PD-1 blockade in resectable stage III melanoma","volume":"36","author":"Helgadottir","year":"2025","journal-title":"Ann Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326005664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326005664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:34:45Z","timestamp":1793374485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326005664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0748798326005664"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111947","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nodal localisation with magnetic seed in patients with stage III melanoma receiving neoadjuvant immune checkpoint inhibitors, a feasibility study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111947"}}